We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+1.5%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$1.24B
AUM Growth
-$1.73B
Cap. Flow
-$1.75B
Cap. Flow %
-141.12%
Top 10 Hldgs %
32.38%
Holding
322
New
31
Increased
40
Reduced
64
Closed
112

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$36.4M
2
CRSP icon
CRISPR Therapeutics
CRSP
+$12.7M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$11.6M
4
CGEM icon
Cullinan Oncology
CGEM
+$9.06M
5
ALEC icon
Alector
ALEC
+$7.87M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$24M
2
CRIS icon
Curis
CRIS
+$13.8M
3
NBP
NovaBridge Biosciences American Depositary Shares
NBP
+$13.5M
4
PRTA icon
Prothena Corp
PRTA
+$11M
5
TVRD
Tvardi Therapeutics
TVRD
+$9.32M

Sector Composition

Rank Sector Weight
1 Healthcare 43.58%
2 Technology 0.24%
3 Consumer Staples 0.11%
4 Financials 0.06%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZLAB icon
201
CALL
Zai Lab
ZLAB
$2.07B
$284K 0.02%
+1,600
New +$257K
ASMB icon
202
Assembly Biosciences
ASMB
$498M
$281K 0.02%
6,039
– –
CRVS icon
203
Corvus Pharmaceuticals
CRVS
$1.1B
$267K 0.02%
100,000
– –
ASLN
204
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$248K 0.02%
30,613
– –
INBX
205
DELISTED
Inhibrx, Inc. Common Stock
INBX
$222K 0.02%
8,076
– –
IVA
206
Inventiva
IVA
$1.07B
$207K 0.02%
15,000
– –
GMDA
207
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$201K 0.02%
31,166
-104,976
-77% -$724K
TRAW icon
208
Traws Pharma
TRAW
$7.34M
$161K 0.01%
929
-2,125
-70% -$481K
SLNO
209
DELISTED
Soleno Therapeutics
SLNO
$140K 0.01%
8,164
– –
BXRX
210
DELISTED
Baudax Bio, Inc. Common Stock
BXRX
$76K 0.01%
71
– –
ABUS icon
211
Arbutus Biopharma
ABUS
$847M
– –
-115,000
Closed -$383K
ACAD icon
212
PUT
Acadia Pharmaceuticals
ACAD
$4.51B
– –
-578,300
Closed -$14.9M
ACHV icon
213
Achieve Life Sciences
ACHV
$634M
– –
-284,151
Closed -$3.29M
AGIO icon
214
CALL
Agios Pharmaceuticals
AGIO
$2.08B
– –
-125,000
Closed -$6.46M
ALT icon
215
Altimmune
ALT
$568M
– –
-181,941
Closed -$2.57M
ANAB icon
216
CALL
AnaptysBio
ANAB
$1.54B
– –
-182,100
Closed -$3.92M
ARDX icon
217
Ardelyx
ARDX
$1.24B
– –
-1,030,436
Closed -$6.82M
ARGX icon
218
CALL
argenx
ARGX
$55.2B
– –
-26,900
Closed -$7.41M
ARGX icon
219
PUT
argenx
ARGX
$55.2B
– –
-34,500
Closed -$9.5M
ARKK icon
220
PUT
ARK Innovation ETF
ARKK
$5.59B
– –
-1,100,000
Closed -$132M
ARVN icon
221
Arvinas
ARVN
$530M
– –
-8,430
Closed -$558K
AUPH icon
222
CALL
Aurinia Pharmaceuticals
AUPH
$1.95B
– –
-100,000
Closed -$1.3M
AZN icon
223
CALL
AstraZeneca
AZN
$269B
– –
-175,000
Closed -$17.4M
BA icon
224
CALL
Boeing
BA
$169B
– –
-60,000
Closed -$15.3M
BEAM icon
225
PUT
Beam Therapeutics
BEAM
$2.68B
– –
-360,000
Closed -$28.8M
7 8
9
10 11

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q2 2021 Portfolio in Review

As of Q2 2021, Ikarian Capital held 322 positions worth $1.24B, down 58% from $2.97B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Ikarian Capital withdrew a net $1.75B in Q2 2021, closing 112 positions and reducing 64 holdings. Its most notable exit was Curis, an estimated $13.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 44% of assets, up from 22% a quarter earlier, followed by Technology and Consumer Staples.

Against the trend, Ikarian Capital opened a new position in ChemoCentryx, Inc. worth $6.31M.

  • Ikarian Capital's largest Q2 2021 buy was ChemoCentryx, Inc.: 471,376 shares worth $6.31M.
  • Ikarian Capital added most to Biogen in Q2 2021, an estimated $36.4M increase.
  • Ikarian Capital's biggest Q2 2021 reduction was Eli Lilly, cutting an estimated $24M.
  • Ikarian Capital fully exited Curis in Q2 2021, selling an estimated $13.8M.
  • Ikarian Capital's ten largest holdings make up 32% of its $1.24B portfolio in Q2 2021.
  • Ikarian Capital opened 31 new positions and closed 112 in Q2 2021.
  • Ikarian Capital's portfolio value fell 58% quarter-over-quarter to $1.24B.

Based on Ikarian Capital's 13F filing for Q2 2021, filed 16 Aug 2021.